Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | Unknown | — |
The patient left the Vivotif vaccine out for 30 hours and took the first dose; The patient left the Vivotif vaccine out for 30 hours and took the first dose; The patient left the Vivotif vaccine out for 30 hours and took the first dose; Case reference number US-BN-2025-000850 is a spontaneous case report initially received from a consumer via Communication (reference number: USBAV25-0867) on 21-Apr-2025 and concerns a female patient of unspecified age. The patient's relevant medical history and concomitant medications were not provided. On an unspecified date, the patient left the vaccine out for 30 hours and she took the first dose (explicitly coded as 'product storage error' and 'product temperature excursion issue'). On an unspecified date, the patient took first dose of defected Vivotif vaccine (batch number: unknown) at an unknown dose, route or site of administration, for unknown indication (explicitly coded as 'product administration error'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. No further information was provided.; Reporter's Comments: A female patient of unspecified age left the vaccine out for 30 hours and she took the first dose which is considered as product storage error and product temperature excursion issue. On an unspecified date, the patient took first dose of defected Vivotif vaccine, at an unknown dose, route or site of administration, for unknown indication which is considered as product administration error. Product temperature excursion issue, product storage error and product administration error are all considered listed per company conventions. At this point, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. The patient's relevant medical history and concomitant medications were not provided. Product temperature excursion issue, product storage error and product administration error are all assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A female patient of unspecified age left the vaccine out for 30 hours and she took the first dose which is considered as product storage error and product temperature excursion issue. On an unspecified date, the patient took first dose of defected Vivotif vaccine, at an unknown dose, route or site of administration, for unknown indication which is considered as product administration error. Product temperature excursion issue, product storage error and product administration error are all considered listed per company conventions. At this point, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. The patient's relevant medical history and concomitant medications were not provided. Product temperature excursion issue, product storage error and product administration error are all assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None.